
Opinion|Videos|October 18, 2024
Safety and Efficacy of RSV Vaccines in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Key Takeaways
- ConquerRSV, AReSVi-006, and RENOIR trials show significant efficacy in preventing RSV-related illness in older adults.
- The vaccines have demonstrated generally well-tolerated safety profiles with manageable side effects.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Provide an overview of the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First At-Home Treatment Device for Depression
2
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
3
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
4
ADCs in Breast Cancer: Shaping the Future of HER2 and TROP-2 Targeted Therapy
5













































































































































































































